FAM218A

Across TCGA pan-cancer cohorts, FAM218A RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated FAM218A data layer compared with 3 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher FAM218A RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM218A expression acts as an unfavorable survival marker, although some lineages such as UCS and KIRP show a favorable association.

MESO, UCS, and UCEC are the cancer types where FAM218A RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	All	0.254	0.461	<.001	111	view →
UCS	OS	Tertile	II,III,IV	0.812	0.293	<.001	70	view →
UCEC	DFS	Median	All	0.543	0.751	<.001	66	view →
KIRP	DFS	Quartile	IV	0.776	0.392	.010	25	view →
OV	DFS	Tertile	IV	0.451	0.236	.016	22	view →
KIRC	OS	Median	All	0.530	0.718	<.001	18	view →
PAAD	DFS	Median	All	0.574	0.396	.001	17	view →
SCLC	DFS	Median	All	0.145	0.378	.011	14	view →
STAD	DFS	Quartile	IV	0.831	0.147	.015	12	view →
LUSC	OS	Median	III,IV	0.477	0.840	.024	11	view →
ACC	DFS	Tertile	IV	0.656	0.089	.024	10	view →
KICH	OS	Tertile	II,III,IV	0.934	0.626	.038	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

FAM218A–MESO (DFS)

Open the MESO breakdown →